Medical

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

July 13, 2023

Bispecific Antibodies Unleashed
Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

Spotlight

DiCE Molecules

DiCE Molecules is a privately-held company focused on the development of small molecule compounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. Utilizing its unique approach, DiCE can amplify the strongest potential drug candidates and, by combining massive diversity with amplification and selection, substantially increase the probability of success.

OTHER WHITEPAPERS
news image

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Read More
news image

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.

Read More
news image

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Read More
news image

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

Read More
news image

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

whitePaper | December 13, 2022

Define the ongoing pandemic of antimicrobial resistance. Discuss how we can address the ongoing pandemicin the Clinical Microbiology Laboratory

Read More
news image

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

Read More

Spotlight

DiCE Molecules

DiCE Molecules is a privately-held company focused on the development of small molecule compounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. Utilizing its unique approach, DiCE can amplify the strongest potential drug candidates and, by combining massive diversity with amplification and selection, substantially increase the probability of success.

Events